# Ozempic and other GLP-1 weight-loss drugs are a covert tool for mass sterilization and depopulation

**Verdict: Contradicted.** The kernel is a mix of real things: GLP-1 drugs were adopted with startling speed, they carry real and documented side effects, and their labels do caution against use in pregnancy. Distrust of the pharmaceutical industry is not irrational. But the specific claim rated here, that semaglutide and tirzepatide are a deliberate scheme to sterilize the population and drive down birth rates, is unsupported by any evidence and cuts against what the data actually show. The drugs are FDA-approved prescription products under continuous safety monitoring; the pregnancy caution is a standard precaution, not a hidden mechanism; and the most-reported fertility surprise linked to these drugs is unexpected pregnancy, the opposite of sterilization. This file weighs the depopulation claim, not the ordinary medical debate about who should take these drugs and for how long.

Category: Science, Space & Technology · Era: 2020s · First circulated: Early 2020s, gathering force from roughly 2023 as GLP-1 use exploded; spread on short-form social video and in anti-pharma and 'depopulation' communities · Believed by: An online audience spanning anti-pharmaceutical and 'depopulation'/'Great Reset' communities, some wellness and anti-diet circles, and a broader public unsettled by how fast the drugs were adopted
URL: https://theconspiratory.com/theory/ozempic-depopulation

## Summary
In a few short years, drugs first developed for type 2 diabetes became the most talked-about medicines in the world, taken by more than one in ten American adults. That speed, layered on real side effects and genuine distrust of the drug industry, gave rise to a darker story: that Ozempic and the other GLP-1 weight-loss drugs are not medicines at all but a covert instrument of mass sterilization and depopulation. The rapid rollout is real. The side effects are real and disclosed. The depopulation scheme is not. The drugs were developed openly over decades of published science, cleared through the public FDA process, and remain under active safety surveillance, and the fertility pattern most often tied to them is not sterility but surprise pregnancy.

## The claim
That semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and GLP-1 receptor agonists generally, were designed and deployed not to treat diabetes and obesity but as a hidden tool of eugenics and depopulation: that they secretly sterilize users, damage fertility, or are otherwise engineered to shrink the human population, with drugmakers and regulators knowingly concealing the true purpose.

## Origin and timeline
- 2005: The FDA approves exenatide (Byetta), the first GLP-1 receptor agonist, derived from a compound first identified in the saliva of the Gila monster. It is the public start of a drug class built on decades of openly published hormone research, long before any weight-loss craze.
- 2017-12: The FDA approves semaglutide as Ozempic for type 2 diabetes. It is a once-weekly injection in the same GLP-1 class, and its effect on appetite and weight quickly draws attention beyond diabetes care.
- 2021-06: The FDA approves semaglutide at a higher dose as Wegovy for chronic weight management, the first new obesity drug of its kind approved since 2014. Demand outstrips supply, and off-label use of Ozempic for weight loss spreads.
- 2022-05: Tirzepatide is approved as Mounjaro for type 2 diabetes, a dual GLP-1 and GIP receptor agonist. Celebrity and social-media attention turns the whole drug class into a cultural phenomenon through 2022 and 2023.
- 2023-11: The FDA approves tirzepatide as Zepbound for chronic weight management. With four blockbuster brands now on the market, use climbs steeply, and public conversation shifts from novelty to unease about long-term effects and appropriate use.
- 2023–2024: As adoption surges, a depopulation narrative takes hold online: posts and videos recast the drugs as a covert sterilization or eugenics program, grafting the old 'globalist depopulation agenda' trope onto the newest mass-market medicine. Separately, reports of 'Ozempic babies', unexpected pregnancies among users, begin circulating, complicating the sterility claim.
- 2025: Survey data show GLP-1 use reaching new highs, with roughly one in eight U.S. adults reporting current use for weight loss, diabetes, or another condition. The scale of the rollout keeps the depopulation claim in wide circulation even as fact-checkers and clinicians push back.

## The evidence, claim by claim
- Claim: The drugs are secretly engineered to sterilize users, so mass adoption will crater the birth rate.
  Evidence: No evidence supports a sterilization mechanism, and the best-known fertility signal points the other way. The phenomenon widely dubbed 'Ozempic babies' describes unexpected pregnancies among users, not infertility. There are plausible, mundane reasons: substantial weight loss can restore ovulation in people whose cycles had stopped, including many with PCOS, and the tirzepatide labels specifically warn that the drug may reduce the effectiveness of oral contraceptives, which would raise the chance of pregnancy, not lower it. A drug that is associated with more surprise pregnancies is a poor candidate for a covert sterilization program.
- Claim: Something rolled out this fast, to this many people, must have a hidden agenda behind it.
  Evidence: Speed is not secrecy. The GLP-1 class grew out of decades of published endocrinology, starting with the incretin hormones and the first approval in 2005, and each brand cleared the FDA's public review process with trial data on file. These are prescription drugs, dispensed by clinicians and monitored after approval through pharmacovigilance systems. The rollout was fast because the drugs worked for their approved uses and demand was enormous, not because a purpose was being concealed. A genuine depopulation plot run through the world's most scrutinized drug-approval system and quarterly earnings calls would be a strange plot indeed.
- Claim: The real, sometimes serious side effects prove the drugs are toxic by design.
  Evidence: The side effects are real, but they are disclosed, not hidden, which is the opposite of what a covert scheme would do. The labels document common gastrointestinal effects like nausea and vomiting, warnings about pancreatitis and gallbladder problems, and a boxed warning about thyroid C-cell tumors seen in rodents. Regulators require those disclosures and track adverse events over time. Documented, labeled, monitored side effects are how ordinary medicines are supposed to work; they are evidence of oversight, not of a plan to harm.
- Claim: The pregnancy warnings on the label prove the makers know the drugs harm fetuses and are using that to cut births.
  Evidence: The pregnancy caution is a standard precaution, and its reasoning is public. The labels advise against use in pregnancy chiefly because animal reproduction studies flagged potential fetal risk and because deliberate weight loss offers no benefit during pregnancy, with a recommended washout before a planned pregnancy given the drug's long half-life. Novo Nordisk also runs an FDA pregnancy exposure registry to gather real-world outcome data. Cautious labeling and active monitoring are ordinary regulatory practice for many drugs; reading them as a confession of a sterilization plot inverts what they actually say.
- Claim: Falling birth rates line up with the arrival of these drugs, which shows the depopulation effect at work.
  Evidence: The timing does not fit. Birth rates across the United States, Europe, and East Asia have been declining for decades, long before any GLP-1 drug existed, driven by well-studied social and economic factors: later marriage, the cost of raising children, expanded education and careers, and changing family norms. A trend that predates a drug by a generation cannot have been caused by it. Blaming a recent medicine for a long-running demographic shift confuses a coincidence of dates for a mechanism.

## Why people believe it
- The adoption curve was genuinely startling. Going from a niche diabetes injection to something more than one in ten adults report taking, in only a few years, feels engineered even when it is just a popular product meeting huge demand, and that strangeness is fertile ground for suspicion.
- Distrust of the pharmaceutical industry is not baseless. Real scandals, most of all the opioid crisis, taught the public that drugmakers can downplay harms for profit, so a story about a hidden agenda lands on prepared soil even when this particular story is unsupported.
- The depopulation narrative predates the drugs and was looking for a host. Long-running 'globalist eugenics' and 'population control' tropes, attached over the years to vaccines, water, and food, slid naturally onto the newest mass-market medicine without needing any new evidence.
- The real, disclosed side effects and the genuine pregnancy cautions give the theory concrete hooks. Each true detail, the nausea, the boxed rodent-tumor warning, the advice to avoid pregnancy, can be lifted out of context and recast as a smoking gun.
- A separate, differently motivated critique lent borrowed language. Some anti-diet and fat-liberation writers framed the drugs' rise as 'eugenics' against fat people, a cultural argument about bias and body size, and that vocabulary was easy to blur into the literal depopulation claim even though the two are not the same.

## Open questions
- Long-term safety data are still accumulating. These drugs are new to mass, sustained use in people without diabetes, and while trials and post-market surveillance are extensive, the multi-decade picture of taking them for years is genuinely still being built. That is an ordinary limit of new medicines, not evidence of a hidden purpose.
- The full picture of GLP-1 effects around fertility, contraception, and pregnancy is not yet complete. The contraceptive-interaction and pregnancy-registry work is ongoing, and clinicians are still characterizing outcomes; these are legitimate medical questions that stand entirely apart from, and do not support, the depopulation claim.
- Appropriate use is unsettled: who should take these drugs, at what body weight, for how long, and what happens to weight and muscle after stopping are real clinical debates. None of that speaks to intent to harm; it is the normal work of fitting a powerful new tool to the right patients.
- Access, cost, and off-label and compounded supply raise real policy and safety concerns, including counterfeit products sold outside the regulated system. Those risks are worth taking seriously on their own terms, separate from any conspiracy about population.

## Sources
- NDA 215256 approval letter: WEGOVY (semaglutide) injection, U.S. Food and Drug Administration (Drugs@FDA) (2021): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215256Orig1s000ltr.pdf
- FDA Approves New Medication for Chronic Weight Management (Zepbound / tirzepatide), U.S. Food and Drug Administration (2023): https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- OZEMPIC (semaglutide) injection: Highlights of Prescribing Information, U.S. Food and Drug Administration (accessdata) (2025): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- GLP-1 Injectable Use Among Adults With Diagnosed Diabetes (NCHS Data Brief No. 537), Centers for Disease Control and Prevention, National Center for Health Statistics (2025): https://www.cdc.gov/nchs/products/databriefs/db537.htm
- Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, KFF (Kaiser Family Foundation) (2024): https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
- Semaglutide (fact sheet on pregnancy and breastfeeding exposure), MotherToBaby, Organization of Teratology Information Specialists (2024): https://mothertobaby.org/fact-sheets/semaglutide/
- Is there really an Ozempic baby boom? The unexpected ways GLP-1s could influence fertility, National Geographic (2024): https://www.nationalgeographic.com/health/article/ozempic-fertility-pregnancy-birth-control
- The Long, Strange History of Bill Gates Population Control Conspiracy Theories, Type Investigations (2020): https://typeinvestigations.org/investigation/2020/05/12/the-long-strange-history-of-bill-gates-population-control-conspiracy-theories/

Rated by The Conspiratory, a neutral, sourced encyclopedia of conspiracy theories. Full page: https://theconspiratory.com/theory/ozempic-depopulation